Cargando…

Sex‐Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum

BACKGROUND: Following a heart failure (HF)‐decompensation, there is scarce data about sex‐related prognostic differences across left ventricular ejection fraction (LVEF) status. We sought to evaluate sex‐related differences in 6‐month mortality risk across LVEF following admission for acute HF. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santas, Enrique, Palau, Patricia, Llácer, Pau, de la Espriella, Rafael, Miñana, Gema, Núñez‐Marín, Gonzalo, Lorenzo, Miguel, Heredia, Raquel, Sanchis, Juan, Chorro, Francisco Javier, Bayés‐Genís, Antoni, Núñez, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075214/ https://www.ncbi.nlm.nih.gov/pubmed/34927464 http://dx.doi.org/10.1161/JAHA.121.022404

Ejemplares similares

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction
por: Miñana, Gema, et al.
Publicado: (2022)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure
por: Bertomeu‐Gonzalez, Vicente, et al.
Publicado: (2020)

Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness
por: de la Espriella‐Juan, Rafael, et al.
Publicado: (2018)

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction
por: Amiguet, Martina, et al.
Publicado: (2023)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)
por: Palau, Patricia, et al.
Publicado: (2020)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study
por: Núñez, Julio, et al.
Publicado: (2016)

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
por: Santas, Enrique, et al.
Publicado: (2020)

Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial
por: del Canto, Irene, et al.
Publicado: (2022)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure
por: Civera, Jose, et al.
Publicado: (2022)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
por: Núñez, Julio, et al.
Publicado: (2017)

Biomarkers to Improve Decision-making in Acute Heart Failure
por: de la Espriella, Rafael, et al.
Publicado: (2023)

Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
por: de la Espriella, Rafael, et al.
Publicado: (2020)

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction
por: Domínguez, Eloy, et al.
Publicado: (2018)

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine
por: Miñana, Gema, et al.
Publicado: (2021)

Prognostic Value of the Interaction between Galectin-3 and Antigen Carbohydrate 125 in Acute Heart Failure
por: Núñez, Julio, et al.
Publicado: (2015)

Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
por: Miñana, Gema, et al.
Publicado: (2022)

Efficacy and Safety of Subcutaneous Infusion of Non-formulated Furosemide in Patients with Worsening Heart Failure: a Real-World Study
por: Civera, Jose, et al.
Publicado: (2021)

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome
por: Gabaldon-Perez, Ana, et al.
Publicado: (2021)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome
por: Núñez, Julio, et al.
Publicado: (2022)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO(2) study
por: Mora-Fernández, Carmen, et al.
Publicado: (2023)

Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion
por: Rios-Navarro, Cesar, et al.
Publicado: (2018)

Refractory congestive heart failure: when the solution is outside the heart
por: Pernias, Vicente, et al.
Publicado: (2019)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Quality of life in patients with heart failure and improved ejection fraction: one‐year changes and prognosis
por: Zamora, Elisabet, et al.
Publicado: (2022)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

Maximal functional capacity in subjects with isolated left bundle branch block: A pilot study
por: Palau, Patricia, et al.
Publicado: (2023)

Homocysteine and long-term recurrent infarction following an acute coronary syndrome
por: Miñana, Gema, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p8sjruhistambnoj6pko58fto3